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We present three patients from Suriname who were diagnosed with Guillain–Barré 
syndrome (GBS) during the Zika virus (ZIKV) outbreak in this country. One patient had 
a positive ZIKV urine real-time RT-PCR (qRT-PCR) result. The other two patients had a 
negative ZIKV urine qRT-PCR but a positive virus neutralization test and presence of IgG 
antibodies against ZIKV in the serum. Considering the evidence of a past ZIKV infection 
and absence of evidence for recent infections with the most common preceding infec-
tions of GBS, it is very likely that these GBS cases were triggered by ZIKV.
Keywords: Zika virus, Guillain–Barré syndrome, Flavivirus infections, acute flaccid paralysis, emerging infectious 
disease
INtRoDUCtIoN
Since the Zika virus (ZIKV) outbreak in South America, an increased incidence of microcephaly and 
the Guillain–Barré syndrome (GBS) is reported in several affected countries in South America (1, 2).
Guillain–Barré syndrome is a heterogeneous postinfectious immune-mediated syndrome 
characterized by rapidly progressive symmetrical muscle weakness and decreased or absent deep 
tendon reflexes (3). GBS is a clinical diagnosis, but supported by investigation of cerebrospinal fluid 
(CSF) for an elevated protein level with normal cell count (albuminocytologic dissociation) and 
by nerve conduction studies. Various types of preceding infection are associated with GBS such as 
Campylobacter jejuni, Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Mycoplasma pneumo-
niae, hepatitis E virus, and now ZIKV (4–6). In addition to supportive care, the treatment of GBS 
includes intravenous immunoglobulins (IVIg) or plasma exchange (PE).
Since the start of the ZIKV outbreak in Suriname in October 2015, clinicians in Suriname have 
noted a 5- to 10-fold increase in GBS incidence until March 2016 [personal communication with 
Dr. Harvey Yang, Neurologist, Academic Hospital Paramaribo, Suriname, March 2016 and Ref. (1)]. 
This case series consists of three consecutive, well-documented patients that were diagnosed with 
GBS in 2016 and who had a preceding infection with ZIKV.
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CLINICaL DesCRIptIoN
Case 1
Early 2016, a male in his forties was admitted to a local hospital 
in Paramaribo, Suriname, because of muscle weakness in the legs 
and paresthesias in the hands and feet. He reported development 
of skin rash, red eyes, and arthralgia 7 days before the start of the 
paresthesias and muscle weakness. Physical examination upon 
admission showed symmetrical muscle weakness in the arms and 
legs; Medical Research Council (MRC) score 4 (ranging from 0; 
paralysis to 5; normal strength), absent deep tendon reflexes in 
the legs and decreased deep tendon reflexes in the arms. During 
admission, the patient developed a unilateral peripheral facial 
nerve paralysis and areflexia in both legs and arms. A lumbar 
puncture was performed 3 days after hospital admission, and an 
elevated protein level was found (1.98 g/L, N < 0.5 g/L) in the CSF 
in absence of cells. Due to the typical presentation of symmetrical 
flaccid muscle weakness with decreased or absent deep tendon 
reflexes, an albuminocytologic dissociation in the CSF and 
absence of a sensory level, fever, encephalopathy, or other clinical 
signs of myelum involvement, the diagnosis of GBS was consid-
ered the most probable. ZIKV real-time RT-PCR (qRT-PCR) was 
performed locally on urine taken at day five after admission and 
was negative (7). A motor nerve conduction study (NCS) was 
performed 13 days after the start of muscle weakness. The NCS 
showed a decreased nerve conduction velocity (NCV) and com-
pound muscle action potential (CMAP) and an increased distal 
motor latency (DML) (see Table S1 in Supplementary Material) 
(8). The results of the NCS were consistent with the criteria for the 
primary demyelinating form of GBS according to the Hadden’s 
criteria (9). A needle EMG was also performed and showed no 
abnormalities. The patient was still able to walk independently 
and, as symptoms remained relatively mild, was not treated with 
IVIg or PE. During admission, the muscle strength of the patient 
improved. He was discharged from the hospital after 11 days and 
followed-up at the neurology outpatient clinic until 12 weeks after 
hospital discharge, at which time he was fully recovered.
Case 2
In February 2016, a male in his 40s was admitted to the neurology 
department of a hospital in Paramaribo, Suriname, because of 
muscle weakness in the legs, which started 7 days prior to admis-
sion. At presentation in the hospital, the patient was unable to 
walk without help. Two weeks before muscle weakness started he 
visited the hospital because of urinary retention. Acute myelitis 
and a cauda syndrome were excluded with an MRI-scan, which 
showed no abnormalities. The week before muscle weakness 
started he had an influenza-like syndrome and had a short 
episode of diplopia. At first physical examination after admis-
sion, muscle weakness was observed in predominantly the legs 
(MRC score 4). Areflexia in both legs and arms was noted. The 
patient complained of paresthesias and pain in the legs but did 
not have a sensory level or other signs of myelum involvement. 
A lumbar puncture was performed 2 days after admission, and a 
high protein level was found in the CSF (4.4 g/L) while the cell 
count was slightly increased (32.7 × 106/L). A urine sample, taken 
at day two after admission, was tested positive for ZIKV RNA 
with a Ct-value of 35.7 (7). Four days after admission his muscle 
power improved (MCR score arms 5, legs; proximal 5, distal 4), 
while the areflexia in arms and legs persisted. Because of the little 
availability of IVIg in Suriname and because PE is not possible 
in Suriname, the patient did not received immunotherapy. A 
motor NCS, performed 15 days after the start of muscle weakness, 
showed severe decreased NCV and a prolonged DML in all tested 
nerves. The CMAP was decreased in predominantly the legs (see 
Table S2 in Supplementary Material). These results were consist-
ent with the demyelinating subtype of GBS (10). At discharge, 
7 days after admission, he was still unable to walk without help 
due to muscle weakness in the legs. Four months after hospital 
discharge he was able to walk a few steps without assistance, but 
he still could not live independently or return to work.
Case 3
In March 2016, a male in his 60s visited a hospital in Paramaribo, 
Suriname, because of right-sided peripheral facial nerve paralysis 
since 1  day. The patient did not report having had ZIKV-like 
symptoms prior to admission. Neurological examination 
revealed absent deep tendon reflexes in the lower extremities but 
no muscle weakness. The patient was admitted to the neurology 
department for observation. At day three of admission he devel-
oped a bilateral peripheral facial nerve paralysis. Four days after 
admission, the patient was unable to walk or stand due to muscle 
weakness in the legs (MRC score 4) and areflexia in all limbs. An 
elevated protein level with a mild increased cell count was found 
in the CSF (protein 2.93 g/L, cells 15.7 × 106/L) taken 5 days after 
admission. The progressive phase of the muscle weakness lasted 
for 6 days after which the patient started to recover. Motor NCS 
showed a decreased dCMAP and NCV and increased DML in 
predominantly the legs but also the arms. The tibial nerve was 
inexcitable in both legs (see Table S3 Supplementary Material). 
Features of demyelination were only found in one nerve, and 
as such the NCS results were classified as equivocal (9). ZIKV 
qRT-PCR was performed locally on urine taken at day four after 
admission and was negative (7). The patient received no PE or 
IVIg because of the limited availability of IVIg. At discharge on 
day 18, the patient was able to walk a small distance with assis-
tance. The patient was followed-up at the neurology outpatient 
clinic until 4 months after hospital discharge, at this time he did 
not have residual deficits anymore.
Laboratory analysis
Real-time RT-PCR for ZIKV in urine was performed in the 
Academic Hospital Paramaribo, Suriname. Plasma, serum, and 
CSF samples were collected from the three patients and sent to the 
WHO collaborating centre for arbovirus reference and research 
at Erasmus Medical Centre in Rotterdam, the Netherlands for 
further testing. The samples were collected at days 8 (case 1), 
5 and 7 (case 2), and 3 (case 3) after hospital admission.
Zika virus qRT-PCR in plasma and CSF was negative in all 
three patients (see Table  1) (7). A ZIKV ELISA (Euroimmun, 
Lübeck, Germany) was used according to the manufacturer’s 
recommendation to detect anti ZIKV IgM and IgG antibodies 
in serum samples (11). Anti ZIKV IgM ELISA was negative in 
taBLe 1 | Results of diagnostic tests.
assay Material Case 1 Case 2 Case 3
ZIKV qRT-PCR Urine NEG POS NEG
Plasma NEG NEG NEG
CSF NEG NEG NEG
Anti ZIKV antibodies (ELISA) Serum IgM NEG IgM NEG IgM NEG
IgG POS IgG POS IgG POS
ZIKA VNT (titer + result) Serum 25, POS 40, POS 256, POS
81, POS
DENV Serum IgM NEG IgM NEG IgM NEG
IgG POS IgG POS IgG POS
NS1 NEG NS1 NEG NS1 NEG
Campylobacter jejuni Serum IgM NEG IgM NEG IgM NEG
IgG POS IgG POS IgG POS
CMV Serum IgM NEG IgM NEG IgM NEG
IgG POS IgG POS IgG POS
EBV Serum IgM NEG IgM NEG IgM NEG
IgG VCA POS IgG VCA POS IgG VCA POS
EBNA POS EBNA POS EBNA NEG
VNT, virus neutralization test; NS1, non-structural protein 1; VCA, viral capsid antigen; EBNA, Epstein–Barr virus nuclear antigen; ZIKV, Zika virus; CMV, cytomegalovirus; EBV, 
Epstein–Barr virus; qRT-PCR, real-time RT-PCR.
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all patients, while anti ZIKV IgG antibodies were present in all 
patients. A ZIKV neutralization test (VNT) based on a Suriname 
ZIKV isolate (GenBank: KU937936.1) was performed to detect 
ZIKV neutralizing antibodies. All three patients had neutralizing 
antibodies against ZIKV with titers ranging from 25 (case 1) 
to 256 (case 3). Serology in all patients was negative for recent 
infections with C. jejuni and showed an infection in the past with 
CMV (high avidity IgG anti CMV) and EBV. All serum samples 
tested negative for dengue virus (DENV) IgM antibodies and 
non-structural protein 1 (NS1) antigen and positive for DENV 
IgG antibodies. ELISA was used to detect the presence of IgM 
and IgG antibodies against GM1, GM2, GD1a, GD1b, GT1b, and 
GQ1b, and paired complexes of all these gangliosides in the acute 
phase serum of the patients (12). These anti-ganglioside antibod-
ies were negative in all patients.
DIsCUssIoN
Here, we presented three patients from Suriname with acute 
flaccid paralysis during the height of the ZIKV outbreak in this 
country. Differential diagnostic considerations were GBS and 
acute (Flavivirus) myelitis. None of the patients had a sensory 
level, increased or pathological reflexes, fever, encephalopathy, 
or other symptoms suggesting an acute myelitis, and there was 
no marked pleocytosis in the CSF. Only motor and no sensory 
NCS were performed in these patients. The results of the motor 
NCS were consistent with GBS in all three patients. Furthermore, 
all patients had progressive symmetrical muscle weakness with 
areflexia, a monophasic disease course, an albuminocytologic 
dissociation in the CSF, and absence of an identified alternative 
diagnosis for muscle weakness. All patients thus scored the high-
est level for diagnostic certainty for GBS (level I) according to 
the diagnostic criteria for GBS of the Brighton collaboration and 
were therefore diagnosed with GBS (13). No anti-ganglioside 
antibodies were found in the serum of these patients, but as anti-
ganglioside antibodies are only found in an estimated 50% of GBS 
cases, their absence does not rule out the diagnosis GBS (14).
Typically, muscle weakness in GBS occurs 1–2  weeks after 
the preceding infection that triggers GBS (3). This delay makes 
it difficult to identify the infection that could have triggered the 
onset of GBS based on molecular methods, as the infection may 
have been cleared by the time of onset of the GBS symptoms. 
Especially in ZIKV suspected GBS cases, it is difficult to deter-
mine if the GBS is indeed caused by a recent ZIKV infection. This 
is due to a relatively small diagnostic time window of qRT-PCR 
for ZIKV in EDTA-plasma (3–5 days), to a lesser extent in urine 
(up to 30 days) and semen (up to 92 days), although the sensitiv-
ity of testing at these later time points remains to be validated 
(15–18). Confirmation of an infection based on serology will 
have a broader window of detection. However, in case of past 
Flavivirus exposure, ZIKV IgM response may be delayed, limited, 
or even absent, further complicating etiological diagnosis (19). 
The diagnostic work-up presented for this case series reflects 
these challenges of identifying possible triggers for the onset of 
GBS in these patients.
Definitive evidence for recent ZIKV infection was obtained 
in one patient who tested positive by qRT-PCR for ZIKV in the 
urine. In cases 1 and 3, it is possible that the diagnostic window 
for reliable ZIKV RNA detection had already expired once the 
GBS symptoms occurred and the samples were collected. No IgM 
antibodies to ZIKV were detected, including the patient with 
confirmed ZIKV shedding by RT-PCR, but all three patients had 
neutralizing antibodies indicating a past ZIKV infection. The 
absence of IgM antibodies is remarkable, although the assays 
that currently are available have demonstrated short-lived IgM 
responses and as mentioned above, IgM response can be absent 
in case of prior Flavivirus exposure (e.g., DENV in these patients) 
(19). A recent infection with the most prevalent preceding 
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infections of GBS—C. jejuni, CMV, and EBV—were excluded 
in the patients, which makes it more plausible that the GBS was 
triggered by a recent ZIKV infection.
The exact pathophysiological mechanism behind ZIKV-
associated GBS remains to be elucidated, but antibody-depend-
ent enhancement (ADE) of ZIKV infection might play a role. 
It has recently been described that DENV antibodies that are 
able to bind ZIKV, but cannot neutralize ZIKV, can promote 
ADE that can result in greater ZIKV replication (20). The three 
patients in this case series all had IgG antibodies against DENV. 
It remains to be seen if the combined effects of past and recent 
Flavivirus exposures plays a role in the pathogenesis of ZIKV-
associated GBS.
CoNCLUsIoN
Taken together, we can conclude that in the three presented cases, 
the relation between ZIKV infection and GBS was confirmed 
in one patient, and was plausible in the two others, given the 
increased GBS incidence during the ZIKV outbreak in Suriname, 
the ruling out of most prevalent preceding infections of GBS and 
the presence of ZIKV neutralizing antibodies in these patients. 
For definitive proof of this association, case–control studies are 
needed, using stringent and standardized diagnostic criteria, 
both for GBS and for the laboratory diagnosis.
etHICs stateMeNt
This study was approved by the Ministry of Health of Suriname. 
All participants signed informed consent prior to participation 
in this study.
aUtHoR CoNtRIBUtIoNs
TL, BJ, CR, MK, EG, CG, and SV wrote the manuscript. MB, 
HY, and HA cared for the patients. TL, LD, TK, HY, and MB col-
lected the data. JC, JR, and SP were responsible for the molecular 
diagnostic tests. EB, RM, CG, and CR were responsible for the 
serological tests. All authors reviewed and approved the final 
version of the manuscript.
aCKNoWLeDGMeNts
The authors thank Anne Tio-Gillen for performing the anti-
ganglioside antibody assay.
sUppLeMeNtaRY MateRIaL
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fneur.2016.00233/
full#supplementary-material.
ReFeReNCes
1. WHO. Situation Report Zika Virus, Microcephaly, Guillain-Barré Virus, 11 
August 2016. World Health Organization (2016). Available from: http://apps.
who.int/iris/bitstream/10665/249518/1/zikasitrep11Aug2016-eng.pdf?ua=1
2. Brasil P, Pereira JP Jr, Moreira ME, Ribeiro Nogueira RM, Damasceno 
L, Wakimoto M, et  al. Zika virus infection in pregnant women in Rio 
de Janeiro. N Engl J Med (2016) 375(24):2321–34. doi:10.1056/NEJMoa 
1602412 
3. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet 
(2016) 388(10045):717–27. doi:10.1016/S0140-6736(16)00339-1 
4. Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P, Schmitz PI, de 
Klerk MA, et  al. The spectrum of antecedent infections in Guillain-Barre 
syndrome: a case-control study. Neurology (1998) 51(4):1110–5. doi:10.1212/
WNL.51.4.1110 
5. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastere S, Valour F, et al. Zika 
virus infection complicated by Guillain-Barre syndrome – case report, French 
Polynesia, December 2013. Euro Surveill (2014) 19(9). doi:10.2807/1560-7917.
ES2014.19.9.20720 
6. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, 
et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection 
in French Polynesia: a case-control study. Lancet (2016) 387(10027):1531–9. 
doi:10.1016/S0140-6736(16)00562-6 
7. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et  al. 
Genetic and serologic properties of Zika virus associated with an epidemic, Yap 
State, Micronesia, 2007. Emerg Infect Dis (2008) 14(8):1232–9. doi:10.3201/
eid1408.080287 
8. Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders. 
3rd ed. London: W.B. Saunders (2013).
9. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, 
et al. Electrophysiological classification of Guillain-Barre syndrome: clinical 
associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre 
Syndrome Trial Group. Ann Neurol (1998) 44(5):780–8. doi:10.1002/
ana.410440512 
10. Bensa S, Hadden RD, Hahn A, Hughes RA, Willison HJ. Randomized con-
trolled trial of brain-derived neurotrophic factor in Guillain-Barre syndrome: 
a pilot study. Eur J Neurol (2000) 7(4):423–6. doi:10.1046/j.1468-1331.2000. 
00096.x 
11. Huzly D, Hanselmann I, Schmidt-Chanasit J, Panning M. High specificity 
of a novel Zika virus ELISA in European patients after exposure to different 
flaviviruses. Euro Surveill (2016) 21(16):30203. doi:10.2807/1560-7917.
ES.2016.21.16.30203 
12. Kuijf ML, van Doorn PA, Tio-Gillen AP, Geleijns K, Ang CW, Hooijkaas H, 
et  al. Diagnostic value of anti-GM1 ganglioside serology and validation 
of the INCAT-ELISA. J Neurol Sci (2005) 239(1):37–44. doi:10.1016/ 
j.jns.2005.07.009 
13. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. 
Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. 
Brain (2014) 137(Pt 1):33–43. doi:10.1093/brain/awt285 
14. van Doorn PA, Jacobs BC. Neuronal endocytosis of anti-ganglioside antibod-
ies: implications for Guillain-Barre syndrome. Brain (2016) 139(Pt 6):1622–5. 
doi:10.1093/brain/aww078 
15. Reusken C, Pas S, GeurtsvanKessel C, Mogling R, van Kampen J, Langerak T, 
et  al. Longitudinal follow-up of Zika virus RNA in semen of a traveller 
returning from Barbados to the Netherlands with Zika virus disease, March 
2016. Euro Surveill (2016) 21(23):30251. doi:10.2807/1560-7917.ES.2016.21. 
23.30251 
16. Charrel RN, Leparc-Goffart I, Pas S, de Lamballerie X, Koopmans M, 
Reusken  C. Background review for diagnostic test development for Zika 
virus infection. Bull World Health Organ (2016) 94(8):574–84D. doi:10.2471/
BLT.16.171207
17. D’Ortenzio E, Matheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, 
Piorkowski G, et al. Evidence of Sexual Transmission of Zika Virus. N Engl 
J Med (2016) 374(22):2195–8. doi:10.1056/NEJMc1604449 
5Langerak et al. Zika Virus and Guillain–Barré Syndrome
Frontiers in Neurology | www.frontiersin.org December 2016 | Volume 7 | Article 233
18. ECDC. Rapid Risk Assessment Zika Virus Disease Epidemic, Seventh Update, 
8 July 2016. (2016). Available from: http://ecdc.europa.eu/en/publications/
Publications/RRA-Zika-virus%20epidemic-seventh-update-final.pdf
19. Euroimmun. Euroimun Test Systems for the Diagnosis of Zika Virus 
Infections. (2016). Available from: https://www.euroimmun.com/documents/
Indications/Infections/Zika-virus/HI_2668_I_UK_B.pdf
20. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, 
Duangchinda T, et  al. Dengue virus sero-cross-reactivity drives antibody- 
dependent enhancement of infection with Zika virus. Nat Immunol (2016) 
17(9):1102–8. doi:10.1038/ni.3515 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
The reviewer VG and the handling Editor declared their shared affiliation, and the 
handling Editor states that the process nevertheless met the standards of a fair and 
objective review.
Copyright © 2016 Langerak, Yang, Baptista, Doornekamp, Kerkman, Codrington, 
Roosblad, Vreden, De Bruin, Mögling, Jacobs, Pas, GeurtsvanKessel, Reusken, 
Koopmans, Van Gorp and Alberga. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The 
use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these 
terms.
